Article

Assessing the total costs of blood delivery to hospital oncology and haematology patients.

Department of Haematological Oncology, St. Bartholomew's Hospital (Queen Mary University of London), London, UK.
Current Medical Research and Opinion (Impact Factor: 2.37). 11/2006; 22(10):1903-9. DOI: 10.1185/030079906X132532
Source: PubMed

ABSTRACT To determine direct costs associated with a blood transfusion session in two hospital settings.
The study was conducted in two United Kingdom hospital sites during April 2004. Transfusion sessions for patients receiving units of red blood cells within either haematology or oncology departments were followed using time and motion techniques to measure the direct costs. Other data were collected from the centres to calculate the cost of disposables, blood wastage and blood bank machines.
Total mean staff cost per transfusion of 2 units was 37.24 pounds sterling (9.68 pounds sterling for blood bank and 27.56 pounds sterling for ward procedures). The mean cost of disposables was 13.25 pounds sterling and the mean cost for blood products was 287.56 pounds sterling. The mean cost of wastage was 11.86 pounds sterling per transfusion. After including other derived costs, such as hospital stay, the mean cost for a transfusion of 2 units of blood was estimated to be 546.12 pounds sterling.
This study estimates the cost of an average blood transfusion of 2 units to be 546.12 pounds sterling. It should be noted that significant indirect costs, such as those incurred by patients, their carers and societal costs, have not been considered. Against the background of finite blood resources and other factors such as patient quality of life, blood transfusion may not represent the best choice for patient care. Alternative treatments should be considered.

0 Bookmarks
 · 
67 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The goal of this study was to estimate the cost of production of 1 unit of blood from a National Health Service perspective in Greece.
    Clinical therapeutics. 06/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Red blood cells and platelet concentrates are frequently used in paediatric oncology. There is little literature on the indications and costs of this adjuvant therapy. Aim: To retrospectively evaluate the indications, amounts and costs of transfusing blood products in 2008 in the Depart-ment of Paediatric Oncology at Tygerberg Children's Hospital, Cape Town. Material and Method: The patient records were analyzed for age, sex, disease and stage, indications for transfusion and type of blood product as well as amount. The costs were obtained from the Blood Bank for each item released for every patient. Results: Thirty-nine children with cancer were transfused, between one unit and 34 units of blood products per patient, during their treatment in 2008. The total cost of this therapy in 2008 was ZAR 941,966 = USD 125,595 = EUR 89,711. The maximum cost per patient amounted to ZAR 70,682 = USD 9,424 = EUR 6,731 and the minimum ZAR 914 = USD 121 = EUR 87. The average expenditure per patient was ZAR 24,125 = USD 3,216 = EUR 2,297. The management of leukemia required the highest usage of blood products per patient. Conclusion: The use of blood products is indispensable during the treatment of numerous haematology – oncology diseases. Their indications should be specified in internal protocols and their actual use should be audited frequently due to the considerable costs.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objetivos: Llevar a cabo una revisión de la literatura sobre el coste de la transfusión sanguínea en España. Se evaluó información de otros países con el fin de comparar las tendencias en los costes. Métodos: Se realizó una búsqueda electrónica en dos bases de datos: PubMed y Ediciones DOYMA. Ante la escasa evidencia para España, se realizó una búsqueda manual en revistas especializadas. El horizonte de búsqueda fue desde el año 2002 al 2007. Veintiséis publicaciones cumplieron los criterios de inclusión: 6 artículos para España, 6 para Estados Unidos, 5 para Reino Unido, 2 para Francia y 1 para Suecia, Noruega, Holanda, Bélgica, Grecia y Canadá. Se incluyó dentro del estudio una revisión de la literatura sobre el coste del concentrado de hematíes (CH) para el Reino Unido, Estados Unidos y Canadá. Resultados: De la revisión para España se estimó que el coste de un CH ha aumentado en un 52,8% de 2001 a 2003; considerando el coste de transfundir un CH el coste aumenta un 29,9% (2003–2006). En comparación con otros países, el coste de un CH en los Estados Unidos ha aumentado un 11,73% (2001–2003). En el Reino Unido ha aumentado un 34,11% (2002–2005), y en Francia ha aumentado un 9,05% (2000–2003). Conclusión: La utilización de una moneda común (€) y los precios constantes al año 2007 permiten realizar una fácil comparación en el tiempo y entre países. El coste de un CH en España se estimó en 150 € por unidad de CH y en 350 € por concentrado transfundido.
    Pharmacoeconomics - Spanish Research Articles 6(2).